vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and GDEV Inc. (GDEV). Click either name above to swap in a different company.

GDEV Inc. is the larger business by last-quarter revenue ($119.9M vs $77.6M, roughly 1.5× Bioceres Crop Solutions Corp.). GDEV Inc. runs the higher net margin — 13.9% vs -9.6%, a 23.5% gap on every dollar of revenue. On growth, GDEV Inc. posted the faster year-over-year revenue change (13.3% vs -16.8%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

GDEV Inc. is a gaming and entertainment holding company. It is a publicly traded company listed on the Nasdaq stock exchange, headquartered in Limassol, Cyprus. The holding was evolved in June 2023 from a video game company Nexters, founded in 2014, one of the top five independent mobile game companies in Europe. Subsidiaries of GDEV include Nexters Studio, which operates offices in Cyprus, Armenia, and Kazakhstan, as well as Cubic Games, Royal Ark, Game Gears and Light Hour Games. The compan...

BIOX vs GDEV — Head-to-Head

Bigger by revenue
GDEV
GDEV
1.5× larger
GDEV
$119.9M
$77.6M
BIOX
Growing faster (revenue YoY)
GDEV
GDEV
+30.1% gap
GDEV
13.3%
-16.8%
BIOX
Higher net margin
GDEV
GDEV
23.5% more per $
GDEV
13.9%
-9.6%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
BIOX
BIOX
GDEV
GDEV
Revenue
$77.6M
$119.9M
Net Profit
$-7.4M
$16.6M
Gross Margin
46.8%
Operating Margin
9.3%
15.5%
Net Margin
-9.6%
13.9%
Revenue YoY
-16.8%
13.3%
Net Profit YoY
-20.2%
13.0%
EPS (diluted)
$-0.12
$0.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
GDEV
GDEV
Q3 25
$77.6M
Q2 25
$119.9M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
Q2 24
$105.8M
Q1 24
$84.0M
Q4 23
$140.2M
Net Profit
BIOX
BIOX
GDEV
GDEV
Q3 25
$-7.4M
Q2 25
$16.6M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
Q2 24
$14.7M
Q1 24
$9.8M
Q4 23
$1.2M
Gross Margin
BIOX
BIOX
GDEV
GDEV
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Q4 23
36.7%
Operating Margin
BIOX
BIOX
GDEV
GDEV
Q3 25
9.3%
Q2 25
15.5%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
14.4%
Q1 24
15.7%
Q4 23
12.0%
Net Margin
BIOX
BIOX
GDEV
GDEV
Q3 25
-9.6%
Q2 25
13.9%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
Q2 24
13.9%
Q1 24
11.6%
Q4 23
0.9%
EPS (diluted)
BIOX
BIOX
GDEV
GDEV
Q3 25
$-0.12
Q2 25
$0.90
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q2 24
$0.81
Q1 24
$0.14
Q4 23
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
GDEV
GDEV
Cash + ST InvestmentsLiquidity on hand
$15.5M
$41.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$-129.4M
Total Assets
$734.9M
$210.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
GDEV
GDEV
Q3 25
$15.5M
Q2 25
$41.6M
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
$50.8M
Q1 24
$16.4M
Q4 23
$24.4M
Stockholders' Equity
BIOX
BIOX
GDEV
GDEV
Q3 25
$288.3M
Q2 25
$-129.4M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q2 24
$-118.7M
Q1 24
$348.5M
Q4 23
$335.3M
Total Assets
BIOX
BIOX
GDEV
GDEV
Q3 25
$734.9M
Q2 25
$210.2M
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
Q2 24
$282.8M
Q1 24
$836.1M
Q4 23
$819.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
GDEV
GDEV
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
GDEV
GDEV
Q3 25
$14.4M
Q2 25
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
Q2 24
Q1 24
$-17.4M
Q4 23
$21.1M
Cash Conversion
BIOX
BIOX
GDEV
GDEV
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×
Q4 23
17.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons